Valuation: Alkermes plc

Capitalization 475.74Cr 405.89Cr 379.39Cr 349.54Cr 650.61Cr 41TCr 732.62Cr 4.53TCr 1.72TCr 19TCr 1.78TCr 1.75TCr 69TCr P/E ratio 2025 *
25x
P/E ratio 2026 * 24.5x
Enterprise value 359.35Cr 306.59Cr 286.57Cr 264.03Cr 491.44Cr 31TCr 553.38Cr 3.42TCr 1.3TCr 14TCr 1.35TCr 1.32TCr 52TCr EV / Sales 2025 *
2.59x
EV / Sales 2026 * 2.26x
Free-Float
90.15%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.32%
1 week+1.46%
Current month+2.17%
1 month-7.82%
3 months-2.76%
6 months+2.67%
Current year+1.63%
More quotes
1 week 28.48
Extreme 28.485
30
1 month 28.48
Extreme 28.485
32.35
Current year 25.56
Extreme 25.56
36.45
1 year 22.9
Extreme 22.9
36.45
3 years 21.75
Extreme 21.75
36.45
5 years 15.35
Extreme 15.35
36.45
10 years 11.98
Extreme 11.98
80.71
More quotes
Manager TitleAgeSince
Chief Executive Officer 63 01/02/1991
Director of Finance/CFO 52 01/02/2024
Chief Tech/Sci/R&D Officer - 01/01/2005
Director TitleAgeSince
Chairman 63 01/09/2011
Director/Board Member 73 26/05/2016
Director/Board Member 62 30/03/2018
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.32%+1.46%+20.34%-8.28% 475.74Cr
-0.39%-1.52%+11.11%+1.79% 4.99TCr
-1.83%-0.09%+63.89%+33.11% 2.91TCr
+0.45%+11.82%+5.09%+8.88% 2.89TCr
-1.09%+3.16%-21.94%-24.79% 2.84TCr
-0.92%-0.95%+25.77%-21.28% 1.29TCr
-1.67%+2.10%-53.99%-32.82% 1.19TCr
-1.94%+10.09%-74.73%-81.26% 1.18TCr
-19.83%+5.92%+19,198.43%+1,738.22% 1.14TCr
-4.85%-12.79%+87.86% - 1.06TCr
Average +0.27%+2.68%+1,926.18%+179.28% 2TCr
Weighted average by Cap. -0.19%+2.40%+1,102.64%+98.95%
See all sector performances

Financials

2025 *2026 *
Net sales 138.5Cr 118.17Cr 110.45Cr 101.76Cr 189.42Cr 12TCr 213.29Cr 1.32TCr 502.07Cr 5.53TCr 519.43Cr 508.7Cr 20TCr 143.83Cr 122.71Cr 114.7Cr 105.68Cr 196.7Cr 12TCr 221.49Cr 1.37TCr 521.37Cr 5.75TCr 539.4Cr 528.25Cr 21TCr
Net income 19Cr 17Cr 16Cr 14Cr 27Cr 1.67TCr 30Cr 185.46Cr 71Cr 778.63Cr 73Cr 72Cr 2.84TCr 20Cr 17Cr 16Cr 15Cr 28Cr 1.74TCr 31Cr 192.67Cr 73Cr 808.91Cr 76Cr 74Cr 2.95TCr
Net Debt -116.39Cr -99Cr -93Cr -86Cr -159.17Cr -9.98TCr -179.24Cr -1.11TCr -421.91Cr -4.65TCr -436.5Cr -427.48Cr -17TCr -150.69Cr -128.57Cr -120.17Cr -110.72Cr -206.08Cr -13TCr -232.06Cr -1.43TCr -546.25Cr -6.02TCr -565.14Cr -553.46Cr -22TCr
More financial data * Estimated data
Logo Alkermes plc
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Employees
1,800
More about the company
Date Price Change Volume
07/25/07 29.23 $ +1.32% 21,49,324
03/25/03 28.85 $ -0.52% 11,22,189
02/25/02 29.00 $ +0.05% 21,65,021
01/25/01 28.98 $ +1.31% 18,90,636

Delayed Quote Nasdaq, July 08, 2025 at 01:30 am IST

More quotes
Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
29.23USD
Average target price
41.07USD
Spread / Average Target
+40.49%
Consensus

Quarterly revenue - Rate of surprise